ðŠ ãŠã€ã«ã¹ææãšèºççèïŒèŠéããããã¡ãªãªã¹ã¯
å¬ã«ãªããšãã€ã³ãã«ãšã³ã¶ãRSãŠã€ã«ã¹ãæ°åã³ãããŠã€ã«ã¹ãªã©ãæ§ã ãªãŠã€ã«ã¹æ§åŒåžåšææçãæµè¡ããŸãããããã®ãŠã€ã«ã¹ææçã¯ãããèªäœãç§ãã¡ã«äžå¿«ãªçç¶ããããããŸãããå®ã¯ããäžã€ãèŠéããããã¡ãªãªã¹ã¯ãæ±ããŠããŸããããã¯ã现èã«ããäºæ¬¡ææãç¹ã«èºççèïŒStreptococcus pneumoniaeïŒã«ãããã®ã§ãã
èºççèã¯ãèºçãäžè³çãé«èçãšãã£ãé節ãªçŸæ£ãåŒãèµ·ãã现èãšããŠç¥ãããŠããŸããéåžžãå¥åº·ãªæäººã§ã¯éŒ»ãåã«èºççèãä¿èïŒcolonizationïŒçްèãäœã«äœã¿çããŠããç¶æ ïŒãããŠããããšã¯çšã§ããããŠã€ã«ã¹ææã«ãã£ãŠãã®ç¶æ³ãå€ããå¯èœæ§ããããŸããæ¬ç ç©¶ã¯ãã€ã³ãã«ãšã³ã¶ãRSãŠã€ã«ã¹ãSARS-CoV-2ïŒæ°åã³ãããŠã€ã«ã¹ïŒãšãã£ãäž»èŠãªãŠã€ã«ã¹ææçã«ããã£ãæäººã®äœå ã§ãèºççèãã©ã®çšåºŠä¿èãããŠããã®ãããããŠãã®é¢é£å åãè¡æž åïŒserotypeïŒçްèã®çš®é¡ãç¹å®ããåé¡ïŒã®ååžã詳现ã«èª¿æ»ããŸããã
ãã®ç ç©¶çµæã¯ããŠã€ã«ã¹ææçãšèºççèææçã®äºé²æŠç¥ãèããäžã§ãéåžžã«éèŠãªç€ºåãäžããŠãããŸãã
ç ç©¶ã®èæ¯ãšç®ç
æäººã«ãããèºççèã®ä¿èã¯ãå°å ã«æ¯ã¹ãŠé »åºŠãäœããšãããŠããŸããããããã€ã³ãã«ãšã³ã¶ãªã©ã®ãŠã€ã«ã¹ææçã«ããããšãæ°éã®ç²èããã¡ãŒãžãåãã现èãä»çãããããªãããšã§ãèºççèã®ä¿èãå¢å ããå¯èœæ§ãææãããŠããŸããããã®ä¿èç¶æ ã¯ããã®åŸã®çŽ°èæ§èºçãªã©ã®äºæ¬¡ææãªã¹ã¯ãé«ããèŠå ãšãªããŸãã
ãããŸã§ã®ç ç©¶ã§ã¯ãç¹å®ã®ãŠã€ã«ã¹ãšèºççèä¿èã®é¢ä¿ãéšåçã«ç€ºãããŠããŸããããã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ïŒIAVïŒãSARS-CoV-2ãRSãŠã€ã«ã¹ïŒRSVïŒãšããäž»èŠãªåŒåžåšãŠã€ã«ã¹ææçãåæã«æ¯èŒããæäººã«ãããèºççèä¿èã®é »åºŠãé¢é£ããèŠå ããããŠæ€åºãããè¡æž åã®çš®é¡ãå æ¬çã«èª¿æ»ããç ç©¶ã¯å€ããããŸããã§ãããæ¬ç ç©¶ã¯ããããã®ãŠã€ã«ã¹ææçãèºççèä¿èã«äžãã圱é¿ãæããã«ããããšãç®çãšããŸããã
ð¬ ã©ã®ããã«èª¿ã¹ãã®ïŒç ç©¶ã®æ¹æ³
ãã®ç ç©¶ã¯ãã¹ãã€ã³ã®å€§åŠç é¢ã§å®æœãããååãç ç©¶ã§ããç ç©¶è ãã¡ã¯ãå³å¯ãªæ¹æ³ãçšããŠããŠã€ã«ã¹ææãšèºççèä¿èã®é¢ä¿ãæããã«ããããšããŸããã
å¯Ÿè±¡ãšæé
ç ç©¶ã®å¯Ÿè±¡ãšãªã£ãã®ã¯ã2023幎12æãã2024幎1æã«ãããŠããã«ããã§å€§åŠç é¢ã®ææ¥éšã«å蚺ããæäººæ£è ã§ããå ·äœçã«ã¯ãã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ïŒIAVïŒãSARS-CoV-2ããŸãã¯RSãŠã€ã«ã¹ïŒRSVïŒã®ããããã®ææãæ€æ»ã§ç¢ºèªãããæ£è ãçµã¿å ¥ããããŸãããããã«ããŠã€ã«ã¹ææã確èªãããªãã£ã33äººã®æ£è ãå¯Ÿç §çŸ€ïŒæ¯èŒå¯Ÿè±¡ãšãªãã°ã«ãŒãïŒãšããŠå«ãããŠã€ã«ã¹ææã®æç¡ã«ããéããæ¯èŒããŸããããã®æéã¯ããããã®ãŠã€ã«ã¹ææçãæµè¡ããææãšéãªã£ãŠããã宿 ãææ¡ããã®ã«é©ããŠããŸããã
æ€æ»æ¹æ³
æ£è ããã¯ã錻åœé ã¬ããæ¶²ïŒnasopharyngeal swabsïŒéŒ»ã®å¥¥ããæ¡åããæ€äœïŒãæ¡åãããŸããããã®ã¬ããæ¶²ãçšããŠãèºççèïŒStreptococcus pneumoniaeïŒã®ååšãæ€åºããããã®RT-PCRæ³ïŒãªã¢ã«ã¿ã€ã ããªã¡ã©ãŒãŒé£éåå¿æ³ïŒãšããé«æåºŠãªæ€æ»ãè¡ãããŸãããRT-PCRæ³ã¯ã现èã®éºäŒåïŒãã®ç ç©¶ã§ã¯lytAéºäŒåãšpiaBéºäŒåïŒãå¢å¹ ããŠæ€åºããããããã埮éã®çްèã§ãç¹å®ã§ããã®ãç¹åŸŽã§ããããã«ãããåã«çްèãååšãããã©ããã ãã§ãªãããã®éïŒèéïŒã®ææšãåŸãããšãã§ããŸããã
ããŒã¿è§£æ
åéãããèšåºããŒã¿ã¯ãCoxæ¯äŸãã¶ãŒãååž°ã¢ãã«ïŒCox proportional hazards regression modelsïŒãšããçµ±èšææ³ãçšããŠè§£æãããŸããããã®ã¢ãã«ã¯ãè€æ°ã®èŠå ãåæã«çµæã«ã©ã®ããã«åœ±é¿ããããè©äŸ¡ããã®ã«é©ããŠãããèºççèä¿èãšé¢é£ããç¬ç«ããå åïŒä»ã®èŠå ã®åœ±é¿ãåãé€ããäžã§ãçŽæ¥çã«é¢é£ããå åïŒãç¹å®ããããã«çšããããŸãããäŸãã°ãå¹Žéœ¢ãæ§å¥ãåºç€çŸæ£ã®æç¡ããããŠã©ã®ãŠã€ã«ã¹ã«ææããŠããããšãã£ãæ§ã ãªæ å ±ãèæ ®ãããèºççèä¿èã®ãªã¹ã¯ãé«ããèŠå ãæŽãåºãããŸããã
ð é©ãã®çµæïŒãŠã€ã«ã¹ææãšèºççèä¿èã®é¢ä¿
ãã®ç ç©¶ã«ãã£ãŠããŠã€ã«ã¹ææãšèºççèä¿èã®éã«æç¢ºãªé¢ä¿ãããããšã瀺ãããŸãããç¹ã«ãã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ãšRSãŠã€ã«ã¹æææã®èºççèä¿èçã®é«ãã¯æ³šç®ã«å€ããŸãã
äž»èŠãªçºèŠã®æŠèŠ
åèšã§616ä»¶ã®ãŠã€ã«ã¹ææãšããœãŒãã調æ»ãããŸãããå èš³ã¯ãã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ïŒIAVïŒææã391ä»¶ãSARS-CoV-2ææã162ä»¶ãRSãŠã€ã«ã¹ïŒRSVïŒææã28ä»¶ããããŠè€æ°ã®ãŠã€ã«ã¹ã«åæææããŠããã±ãŒã¹ã35ä»¶ã§ããããããã®æ£è ã®ãã¡ã85人ããèºççèã®ä¿èãæ€åºãããŸããã
ãŠã€ã«ã¹å¥ã®ä¿èç
èºççèã®ä¿èçã¯ããŠã€ã«ã¹ææã®çš®é¡ã«ãã£ãŠç°ãªããŸãããæãé«ãä¿èçã瀺ããã®ã¯ã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ïŒIAVïŒæææ£è ã§14.8%ã§ãããæ¬¡ãã§RSãŠã€ã«ã¹ïŒRSVïŒæææ£è ã10.7%ãSARS-CoV-2æææ£è ã9.3%ãšããçµæã§ããããŠã€ã«ã¹é°æ§ã®å¯Ÿç §çŸ€ãšæ¯èŒãããšããŠã€ã«ã¹ææã確èªãããæ£è ã®æ¹ããèºççèã®èéïŒlytAéºäŒåã®CTå€äžå€®å€23.1 [18.7-27.4]ïŒãææã«é«ãããšã倿ããŸãããCTå€ïŒCycle Thresholdå€ïŒã¯ãPCRæ€æ»ã§éºäŒåãæ€åºããããŸã§ã®ãµã€ã¯ã«æ°ã瀺ããå€ãäœãã»ã©æ€äœäžã®èéãå€ãããšãæå³ããŸãããã®ããšããããŠã€ã«ã¹ææãèºççèã®å¢æ®ãä¿ããŠããå¯èœæ§ã瀺åãããŸãã
èºççèä¿èãšé¢é£ããå å
çµ±èšè§£æã®çµæãèºççèä¿èãšç¬ç«ããŠé¢é£ããããã€ãã®èŠå ãç¹å®ãããŸããã以äžã®è¡šã«äž»èŠãªçµæããŸãšããŸãã
| é¢é£å å | ãªããºæ¯ (OR) | 95%ä¿¡é Œåºé (95%CI) | é¢é£æ§ |
|---|---|---|---|
| ã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ (IAV) ææ | 3.52 | 1.30-9.17 | èºççèä¿èãšææã«é¢é£ |
| RSãŠã€ã«ã¹ (RSV) ææ | 4.04 | 1.11-13.50 | èºççèä¿èãšææã«é¢é£ |
| 65æ³æªæºã®æäººã«ãããå¥³æ§ | ç·æ§ã®OR 0.43 | 0.19-0.90 | 女æ§ã®æ¹ãä¿èãšé¢é£ïŒç·æ§ã¯ä¿èãªã¹ã¯ãäœãïŒ |
| 65æ³ä»¥äžã®æäººã«ãããRSVææ | 5.56 | 1.03-27.31 | é«éœ¢è ã§RSVææãç¹ã«åŒ·ãä¿èãšé¢é£ |
â»ãªããºæ¯ïŒORïŒïŒããäºè±¡ã®èµ·ããããããç€ºãææšãORã1ãã倧ããå Žåããã®å åããããšäºè±¡ãèµ·ãããããããšãæå³ããŸãã
â»95%ä¿¡é ŒåºéïŒ95%CIïŒïŒãªããºæ¯ã®æšå®å€ã®ä¿¡é Œæ§ã瀺ãç¯å²ããã®ç¯å²ã«1ãå«ãŸããªãå Žåãçµ±èšçã«ææãªé¢é£ããããšå€æãããŸãã
ãã®è¡šãããã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ãšRSãŠã€ã«ã¹ææããèºççèä¿èã®ãªã¹ã¯ãããããçŽ3.5åãçŽ4åã«é«ããããšãããããŸãããŸããè峿·±ãããšã«ã65æ³æªæºã®æäººã§ã¯å¥³æ§ã®æ¹ãèºççèãä¿èããããåŸåãèŠãããŸããïŒç·æ§ã¯ä¿èãªã¹ã¯ãäœãïŒãããã«ã65æ³ä»¥äžã®é«éœ¢è ã«ãããŠã¯ãRSãŠã€ã«ã¹ææãèºççèä¿èãšç¹ã«åŒ·ãé¢é£ããŠããããã®ãªã¹ã¯ã¯çŽ5.5åã«ããªãããšã瀺ãããŸããã
æ€åºãããè¡æž å
æ€åºãããèºççèã®è¡æž åã¯éåžžã«å€æ§ã§ãããéèŠãªç¹ãšããŠããããã®è¡æž åã®å€ãã¯ãçŸåšåºã䜿çšãããŠããèºççèçµååã¯ã¯ãã³ïŒPCVïŒPneumococcal Conjugate VaccineïŒã«å«ãŸããŠããªãã¿ã€ãã§ãã£ãããšãæããããŸããããã¯ãæ¢åã®ã¯ã¯ãã³ã ãã§ã¯ã«ããŒããããªãè¡æž åãããŠã€ã«ã¹æææã«ä¿èãããããå¯èœæ§ãããããšã瀺åããŠããŸãã
ð¡ ãã®ç ç©¶ã瀺åããããšïŒèå¯
æ¬ç ç©¶ã®çµæã¯ããŠã€ã«ã¹æ§åŒåžåšææçããæäººã«ãããèºççèã®ä¿èãä¿é²ããéèŠãªèŠå ã§ããããšãæç¢ºã«ç€ºããŸãããç¹ã«ã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ãšRSãŠã€ã«ã¹ææããSARS-CoV-2ææãšæ¯èŒããŠãããé«ãèºççèä¿èçãšé¢é£ããŠããããšã¯æ³šç®ãã¹ãç¹ã§ãã
ãªãã€ã³ãã«ãšã³ã¶ãRSãŠã€ã«ã¹ãèºççèä¿èã匷ãä¿ãã®ã§ããããããããã®ãŠã€ã«ã¹ã¯ãæ°éã®ç²èäžç®çްèã«çŽæ¥çãªæå·ãäžããããšãç¥ãããŠããŸããæå·ããç²èã¯ã现èãä»çãããããªã£ãããå ç«çްèã®åããäœäžãããããããšã§ãèºççèã墿®ããããç°å¢ãäœãåºããšèããããŸãããŸãããŠã€ã«ã¹ææã«ãã£ãŠåŒãèµ·ããããççåå¿ããèºççèã®å¢æ®ãå©ããå¯èœæ§ãææãããŠããŸããSARS-CoV-2æææã®ä¿èçãçžå¯Ÿçã«äœãã£ãã®ã¯ãSARS-CoV-2ãæ°éäžç®ã«äžãã圱é¿ã®è³ªçãªéãããå ç«å¿çã®ç¹æ§ãç°ãªããããããããŸããããããã¯ãç ç©¶æéäžã«SARS-CoV-2ã«å¯Ÿããéå£å ç«ãé«ãŸã£ãŠããããšã圱é¿ããŠããå¯èœæ§ããããŸãã
é«éœ¢è ã«ãããRSãŠã€ã«ã¹ææãšèºççèä¿èã®åŒ·ãé¢é£ã¯ãç¹ã«éèŠãªçºèŠã§ããé«éœ¢è ã¯ãå 霢ã«äŒŽãå ç«æ©èœã®äœäžãåºç€çŸæ£ã®ååšã«ãããææçãéçåããããåŸåããããŸããRSãŠã€ã«ã¹ææãé«éœ¢è ã®èºççèä¿èãèããå¢å ããããšããããšã¯ãRSãŠã€ã«ã¹ææãããã®åŸã®èºççèã«ããéçææçïŒçŽ°èæ§èºçãªã©ïŒã®ãªã¹ã¯ãå€§å¹ ã«é«ãããã²ãŒããŠã§ã€ããšãªãåŸãããšã瀺åããŠããŸããããã¯ãé«éœ¢è ã«å¯ŸããRSãŠã€ã«ã¹ã¯ã¯ãã³æ¥çš®ã®éèŠæ§ãæ¹ããŠæµ®ã圫ãã«ãããã®ã§ãã
æ€åºãããè¡æž åããæ¢åã®èºççèçµååã¯ã¯ãã³ïŒPCVïŒã«å«ãŸããªããã®ãå€ãã£ããšããç¹ããå ¬è¡è¡çäžã®èª²é¡ãæèµ·ããŸããçŸåšã®ã¯ã¯ãã³ã¯ãéçåããããç¹å®ã®è¡æž åãã¿ãŒã²ããã«ããŠããŸããããŠã€ã«ã¹æææã«ä¿èãããããéPCVè¡æž åã«ããææçã®ãªã¹ã¯ãèæ ®ã«å ¥ããå¿ èŠããããŸããããã¯ãå°æ¥çãªã¯ã¯ãã³ã®éçºããæ¢åã®èºççèã¯ã¯ãã³æ¥çš®æŠç¥ã®èŠçŽãã«ã€ãªããå¯èœæ§ãç§ããŠããŸãã
ãã®ç ç©¶ã¯ããŠã€ã«ã¹ææçã®äºé²ããåã«ãŠã€ã«ã¹ãã®ãã®ã«ããçç¶ãé²ãã ãã§ãªããèºççèã«ããäºæ¬¡ææã®ãªã¹ã¯ãäœæžããäžã§ã極ããŠéèŠã§ããããšã瀺ããŠããŸããç¹ã«ãã€ã³ãã«ãšã³ã¶ãRSãŠã€ã«ã¹ãæµè¡ããææã«ã¯ããããã®ãŠã€ã«ã¹ææçãšèºççèææçã®äž¡æ¹ã«å¯Ÿããäºé²çã匷åããå¿ èŠããããšèšããã§ãããã
ð€ ç§ãã¡ã®å®ç掻ã«ã©ã掻ããïŒã¢ããã€ã¹
ãã®ç ç©¶çµæã¯ãç§ãã¡ã®å¥åº·ãå®ãããã«ãæ¥ã ã®ç掻ã§å®è·µã§ããå ·äœçãªå¯Ÿçã®éèŠæ§ãæããŠãããŸãããŠã€ã«ã¹æ§åŒåžåšææçãšèºççèææçã®ãªã¹ã¯ãæžããããã«ã以äžã®ç¹ã«æ³šæããŸãããã
- ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®æ¥çš®ãæ€èšããïŒ ã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ææã¯èºççèä¿èãšåŒ·ãé¢é£ããŠããŸãããæ¯å¹Žæµè¡åã«ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæ¥çš®ããããšã§ãã€ã³ãã«ãšã³ã¶ãã®ãã®ã®çºçãéçåãé²ãã ãã§ãªããèºççèã«ããäºæ¬¡ææã®ãªã¹ã¯ãäœæžã§ããå¯èœæ§ããããŸãã
- RSãŠã€ã«ã¹ã¯ã¯ãã³ã®æ¥çš®ãæ€èšããïŒç¹ã«é«éœ¢è ïŒïŒ é«éœ¢è ã§ã¯RSãŠã€ã«ã¹ææãèºççèä¿èãšéåžžã«åŒ·ãé¢é£ããŠããŸãããRSãŠã€ã«ã¹ã¯ã¯ãã³ã¯æè¿æ¿èªãããé«éœ¢è ãåŠå©Šãå¯Ÿè±¡ã«æ¥çš®ãæšå¥šãããŠããŸãããèªèº«ããå®¶æã®ç¶æ³ã«åãããŠãå»åž«ãšçžè«ãæ¥çš®ãæ€èšããŸãããã
- èºççèã¯ã¯ãã³ã®æ¥çš®æšå¥šã確èªããïŒ èºççèã¯ã¯ãã³ã«ã¯ãå°å ã ãã§ãªãæäººåãã®å®ææ¥çš®ãä»»ææ¥çš®ããããŸããç¹ã«é«éœ¢è ãåºç€çŸæ£ãæã€æ¹ã¯ãèºççèææçã®éçåãªã¹ã¯ãé«ããããæ¥çš®å¯Ÿè±¡ãšãªãå ŽåããããŸãããããã€ãå»ã«çžè«ãããèªèº«ã®æ¥çš®ç¶æ³ã確èªããŸãããã
- åºæ¬çãªææå¯Ÿçã培åºããïŒ ææŽãããããããã¹ã¯ã®ççšã人混ã¿ãé¿ãããææ°ãããŸãã«è¡ããšãã£ãåºæ¬çãªææå¯Ÿçã¯ããŠã€ã«ã¹ææçã®äºé²ã«éåžžã«å¹æçã§ãããããã®å¯Ÿçã¯ãèºççèãå«ãä»ã®çŽ°èææçã®äºé²ã«ãã€ãªãããŸãã
- äœèª¿äžè¯æã¯ç¡çããäŒé€ããæ©æã«å蚺ããïŒ å³ãçºç±ãªã©ã®çç¶ãããå Žåã¯ãç¡çããèªå® ã§äŒé€ããå¿ èŠã«å¿ããŠå»çæ©é¢ãå蚺ããŸããããæ©æã«èšºæãåããé©åãªæ²»çãéå§ããããšã§ãéçåãäºæ¬¡ææã®ãªã¹ã¯ãäœæžã§ããŸãã
- ãã©ã³ã¹ã®åããé£äºãšååãªç¡ç ïŒ å ç«åãç¶æããããã«ã¯ããã©ã³ã¹ã®åããé£äºãšååãªç¡ç ãäžå¯æ¬ ã§ããå¥åº·çãªçæŽ»ç¿æ £ãå¿ãããäœã®æµæåãé«ããŸãããã
ð§ ç ç©¶ã®éçãšä»åŸã®èª²é¡
æ¬ç ç©¶ã¯éèŠãªç¥èŠããããããŸããããããã€ãã®éçç¹ãååšããŸãããŸããåäžã®ç é¢ã®ææ¥éšãå蚺ããæ£è ã察象ãšããç ç©¶ã§ãããããçµæãä»ã®å°åãç°ãªãå»çç°å¢ã«ããã®ãŸãŸåœãŠã¯ãŸããã¯æ éã«è©äŸ¡ããå¿ èŠããããŸãããŸããç ç©¶æéã2023幎12æãã2024幎1æãšããéå®çãªæéã§ãã£ããããå£ç¯æ§ã幎ããšã®æµè¡ç¶æ³ã®å€åãçµæã«åœ±é¿ãäžããŠããå¯èœæ§ãèããããŸãã
æ€åºãããèºççèã®è¡æž åã倿§ã§ãããæ¢åã®èºççèçµååã¯ã¯ãã³ã«å«ãŸããªãã¿ã€ããå€ãã£ããšããçµæã¯ãä»åŸã®ã¯ã¯ãã³éçºãæ¥çš®æŠç¥ã«ãããŠéèŠãªèª²é¡ãæèµ·ããŸãããããã®éPCVè¡æž åãå®éã«éçææçãåŒãèµ·ããé »åºŠãããã®ç åæ§ã«ã€ããŠããããªã詳现ãªç ç©¶ãå¿ èŠã§ãã
ããã«ãæ¬ç ç©¶ã¯èºççèã®ãä¿èãã«çŠç¹ãåœãŠãŠããŸãããä¿èãå®éã«ãææçã®çºçãã«ã©ã®çšåºŠã€ãªããã®ãããã®ã¡ã«ããºã ããªã¹ã¯å åã«ã€ããŠã¯ãããé·æçãªè¿œè·¡èª¿æ»ãå€§èŠæš¡ãªç ç©¶ãæ±ããããŸãããŠã€ã«ã¹ææãèºççèã®ç åæ§ïŒç æ°ãåŒãèµ·ããèœåïŒã«ã©ã®ãããªåœ±é¿ãäžããã®ããååã¬ãã«ã§ã®è©³çްãªè§£æãä»åŸã®èª²é¡ãšãªãã§ãããã
ãŸãšã
ä»åã®ç ç©¶ã¯ããŠã€ã«ã¹æ§åŒåžåšææçãç¹ã«ã€ã³ãã«ãšã³ã¶AãŠã€ã«ã¹ãRSãŠã€ã«ã¹ã«ææããæäººã«ãããŠãèºççèã®ä¿èãªã¹ã¯ãé«ãŸãããšãæããã«ããŸããããã®çºèŠã¯ããŠã€ã«ã¹ææçã®äºé²ããèºççèã«ããäºæ¬¡ææãé²ãäžã§æ¥µããŠéèŠã§ããããšã瀺åããŠããŸãã
ç¹ã«é«éœ¢è ã§ã¯ãRSãŠã€ã«ã¹ææãèºççèä¿èãšéåžžã«åŒ·ãé¢é£ããŠãããé«éœ¢è ã«å¯ŸããRSãŠã€ã«ã¹ã¯ã¯ãã³ã®éèŠæ§ãæ¹ããŠåŒ·èª¿ãããã®ã§ãããŸããæ€åºãããèºççèã®è¡æž åã倿§ã§ãããæ¢åã®ã¯ã¯ãã³ã§ã«ããŒã§ããªãã¿ã€ããå€ãã£ãããšã¯ãä»åŸã®ã¯ã¯ãã³æŠç¥ãèããäžã§éèŠãªèª²é¡ãšãªããŸãã
ç§ãã¡ã¯ãã€ã³ãã«ãšã³ã¶ãRSãŠã€ã«ã¹ãèºççèã«å¯Ÿããã¯ã¯ãã³æ¥çš®ã®æ€èšããããŠææŽãããã¹ã¯ççšãšãã£ãåºæ¬çãªææå¯Ÿçã培åºããããšã§ããããã®ææçããèªèº«ã®å¥åº·ãå®ãããšãã§ããŸãããã®ç ç©¶çµæãåèã«ããã广çãªææçäºé²å¯Ÿçãå®è·µããŠãããŸãããã
é¢é£ãªã³ã¯é
- åçåŽåç
- åœç«ææçç ç©¶æ
- æ¥æ¬åŒåžåšåŠäŒ
- æ¥æ¬ææçåŠäŒ
- ç±³åœçŸç 察çã»ã³ã¿ãŒ (CDC)
æžèªæ å ±
| DOI | 10.3389/fcimb.2026.1929747 |
|---|---|
| PMID | 42834919 |
| PubMed URL | https://pubmed.ncbi.nlm.nih.gov/42834919/ |
| çºè¡å¹Ž | 2026 |
| èè å | España-Bonilla RocÃo, Calvo-Silveria Sara, González-DÃaz Aida, Guevara-Figueras Júlia, Fernández-Delgado LucÃa, Medina-Gómez Catalina, Calatayud Laura, Niubó Jordi, Gasa MercÚ, Abelenda-Alonso Gabriela, DomÃnguez M Ãngeles, Peñafiel Judith, Ardanuy Carmen, Cà mara Jordi |
| èè æå± | Department of Clinical Microbiology, Bellvitge University Hospital -IDIBELL, L'Hospitalet de Llobregat, Spain.; Biostatistics Unit, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Spain.; Respiratory Department, Bellvitge Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain.; Department of Infectious Diseases, Bellvitge University Hospital -IDIBELL, L'Hospitalet de Llobregat, Spain. |
| éèªå | Front Cell Infect Microbiol |